The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Open accessAbstract
OBJECTIVES: Human anti-chimeric antibodies (HACAs) and subtherapeutic infliximab concentrations are associated with decreased duration of response. We evaluated the clinical utility of measuring HACA and infliximab concentrations. METHODS: The medical records of patients with inflammatory bowel disease (IBD) who had HACA and infliximab concentrations measured were reviewed to determine whether the result affected clinical management. RESULTS: One hundred fifty-five patients had HACA and infliximab concentrations measured. The main indications for testing were loss of response to infliximab (49%), partial response after initiation of infliximab (22%), and possible autoimmune/delayed hypersensitivity reaction (10%). HACAs were identified in 35 patients (23%) and therapeutic infliximab concentrations in 51 patients (33%). Of 177 tests assessed, the results impacted treatment decisions in 73%. In HACA-positive patients, change to another anti-tumor necrosis factor (TNF) agent was associated with a complete or partial response in 92% of patients, whereas dose escalation had a response of 17%. In patients with subtherapeutic infliximab concentrations, dose escalation was associated with complete or partial clinical response in 86% of patients whereas changing to another anti-TNF agent had a response of 33%. Patients with clinical symptoms and therapeutic infliximab concentrations were continued at the same dose 76% of the time and had no evidence of active inflammation by endoscopic/radiographic assessment 62% of the time. CONCLUSIONS: Measurement of HACA and infliximab concentration impacts management and is clinically useful. Increasing the infliximab dose in patients who have HACAs is ineffective, whereas in patients with subtherapeutic infliximab concentrations, this strategy may be a good alternative to changing to another anti-TNF agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationInfluence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Self-citationMaintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Self-citationAdalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Self-citationSandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Self-citationNatalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Self-citation
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Kobayashi, T., Siegmund, B., Le Berre, C., Wei, S. C., Ferrante, M., Shen, B., Bernstein, C. N., Danese, S., Peyrin-Biroulet, L., & Hibi, T. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0205-x · Cited by 1,649
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Roda, G., Jharap, B., Neeraj, N., & Colombel, J.-F. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.63 · Cited by 723
Ben-Horin, S., & Chowers, Y. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04612.x · Cited by 620
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
Self-citationSteenholdt, C., Brynskov, J., Thomsen, O. Ø., Munck, L. K., Fallingborg, J., Christensen, L. A., Pedersen, G., Kjeldsen, J., Jacobsen, B. A., Oxholm, A. S., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305279 · Cited by 460
The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
Lewis, J. D. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.058 · Cited by 458
Optimizing anti-TNF treatments in inflammatory bowel disease
Ben-Horin, S., Kopylov, U., & Chowers, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.06.002 · Cited by 419
Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., Panaccione, R., Steinhart, A. H., Tse, F., Feagan, B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.001 · Cited by 413
Self-citationGarcês, S., Demengeot, J., & Benito-Garcia, E. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202220 · Cited by 411
D'Haens, G. R., Panaccione, R., Higgins, P. D. R., Vermeire, S., Gassull, M., Chowers, Y., Hanauer, S. B., Herfarth, H., Hommes, D. W., Kamm, M., et al. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.392 · Cited by 409
Self-citationTurner, D., Levine, A., Escher, J. C., Griffiths, A. M., Russell, R. K., Dignass, A., Dias, J. A., Bronsky, J., Braegger, C. P., Cucchiara, S., et al. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3182662233 · Cited by 382
Park, J. Y., & Kricka, L. J. (2013) · The Immunoassay Handbook · doi:10.1016/b978-0-08-097037-0.00027-0 · Cited by 365
Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Strand, V., Balsa, A., Al-Saleh, J., Barile-Fabris, L., Horiuchi, T., Takeuchi, T., Lula, S., Hawes, C., Kola, B., & Marshall, L. (2017) · BioDrugs · doi:10.1007/s40259-017-0231-8 · Cited by 353
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Vande Casteele, N., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P., & Vermeire, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.12 · Cited by 346
Adedokun, O. J., Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Xu, Z., Marano, C. W., Johanns, J., Zhou, H., Davis, H. M., Cornillie, F., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.035 · Cited by 341
Self-citationNanda, K. S., Cheifetz, A. S., & Moss, A. C. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.363 · Cited by 336
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
Yanai, H., Lichtenstein, L., Assa, A., Mazor, Y., Weiss, B., Levine, A., Ron, Y., Kopylov, U., Bujanover, Y., Rosenbach, Y., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.029 · Cited by 316
Ben–Horin, S., Waterman, M., Kopylov, U., Yavzori, M., Picard, O., Fudim, E., Awadie, H., Weiss, B., & Chowers, Y. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.020 · Cited by 310
Ding, N. S., Hart, A., & De Cruz, P. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13445 · Cited by 309
Vande Casteele, N., Herfarth, H., Katz, J., Falck-Ytter, Y., & Singh, S. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.031 · Cited by 295
Vande Casteele, N., Khanna, R., Levesque, B. G., Stitt, L., Zou, G. Y., Singh, S., Lockton, S., Hauenstein, S., Ohrmund, L., Greenberg, G. R., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307883 · Cited by 289
Self-citationMitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14368 · Cited by 282
Burak, K. W., Swain, M. G., Santodomino-Garzon, T., Lee, S. S., Urbanski, S. J., Aspinall, A. I., Coffin, C. S., & Myers, R. P. (2013) · Canadian Journal of Gastroenterology · doi:10.1155/2013/512624 · Cited by 167
Do Not Assume Symptoms Indicate Failure of Anti–Tumor Necrosis Factor Therapy in Crohn's Disease
Bruining, D. H., & Sandborn, W. J. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.01.019 · Cited by 20
Self-citationMonoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Metadata
- Authors
- Afif, W., Loftus, E. V., Faubion, W. A., Kane, S. V., Bruining, D. H., Hanson, K. A., & Sandborn, W. J.
- Venue
- American Journal of Gastroenterology
- Published
- 2010-05
- Volume
- 105
- Issue
- 5
- Pages
- 1133-1139
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2118559127
- Cited by
- 486
- References
- 28
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.